Literature DB >> 1416300

Hospital delays and problems with thrombolytic administration in patients receiving thrombolytic therapy: a multicenter prospective assessment. Virginia Thrombolytic Study Group.

E R Gonzalez1, L A Jones, J P Ornato, G C Bleecker, M J Strauss.   

Abstract

STUDY
OBJECTIVES: To assess the timing of key decisions and clinical events in the treatment of acute myocardial infarction with thrombolytic therapy.
DESIGN: Prospective study of emergency department patients.
SETTING: EDs in 11 urban and two rural hospitals. TYPES OF PARTICIPANTS: Patients with presumed acute myocardial infarction for whom a decision was made in the ED to administer thrombolytic therapy.
MEASUREMENTS AND MAIN RESULTS: Statistical analyses included determination of frequency of response, cross tabulation analysis, and Wilcoxon rank sum tests. In 210 thrombolytic-treated patients (mean age, 57 +/- 14.1 years), a median time of 155 minutes elapsed between pain onset and therapy; 67% of the delay was pre-ED arrival. The median time between ED arrival and the initial ECG was six minutes. The median time required for physicians to make a treatment decision was 20 minutes, followed by another median time of 20 minutes for staff to begin drug infusion. The median total hospital (door-to-needle) time was 50 minutes. Significantly shorter delays occurred in urban, teaching, and high-volume hospitals; when thrombolytics were stocked and/or started in the ED; and when emergency physicians treated without involving private attending physicians. Although 95% of patients received tissue plasminogen activator, six patients treated with anisoylated plasminogen-streptokinase activator complex experienced a significantly faster door-to-needle time (P less than .05).
CONCLUSION: Thrombolytics should be stocked and started in the ED. Emergency physicians should generally make the decision to administer thrombolytic therapy with reference to accepted protocols without awaiting an ED consultation from either private attendings or cardiologists.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1416300     DOI: 10.1016/s0196-0644(05)81749-4

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  10 in total

1.  Reasonable "door-to-needle" time for thrombolytic therapy.

Authors:  A F Grunfeld
Journal:  CMAJ       Date:  1996-07-01       Impact factor: 8.262

2.  Thrombolysis in acute myocardial infarction: the safety and efficiency of treatment in the accident and emergency department.

Authors:  J A Edhouse; M Sakr; J Wardrope; F P Morris
Journal:  J Accid Emerg Med       Date:  1999-09

3.  Changing the site of delivery of thrombolytic treatment for acute myocardial infarction from the coronary care unit to the emergency department greatly reduces door to needle time.

Authors:  C T Hourigan; D Mountain; P E Langton; I G Jacobs; I R Rogers; G A Jelinek; P L Thompson
Journal:  Heart       Date:  2000-08       Impact factor: 5.994

4.  Time to treatment and cost of thrombolysis: a multicenter comparison of tPA and rPA.

Authors:  A Seyedroudbari; E R Kessler; A N Mooss; R L Wundeman; M Bala; D E Hilleman
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

5.  Emergency department thrombolysis improves door to needle times.

Authors:  A R Corfield; C A Graham; J N Adams; I Booth; A C McGuffie
Journal:  Emerg Med J       Date:  2004-11       Impact factor: 2.740

6.  Impact of a Simple Inexpensive Quality Assurance Effort on Physician's Choice of Thrombolytic Agents and Door-to-Needle Time: Implication for Costs of Management.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-05       Impact factor: 2.300

7.  Feasibility and timing of prehospital administration of reteplase in patients with acute myocardial infarction.

Authors:  Donald G Rosenberg; Esther Levin; Ana Lausell; Allen Brown; John Gardner; Esther Perez; Mark Veenendaal; Yee S C Ong; Mary Gunn
Journal:  J Thromb Thrombolysis       Date:  2002-06       Impact factor: 2.300

8.  Initiating thrombolytic therapy for acute myocardial infarction: whose job is it anyway?

Authors:  E Letovsky; T Allen
Journal:  CMAJ       Date:  1996-02-15       Impact factor: 8.262

9.  Recommendations for ensuring early thrombolytic therapy for acute myocardial infarction. The Heart and Stroke Foundation of Canada, the Canadian Cardiovascular Society and the Canadian Association of Emergency Physicians for the Emergency Cardiac Care Coalition.

Authors: 
Journal:  CMAJ       Date:  1996-02-15       Impact factor: 8.262

10.  Evaluation of fibrinolytic medical therapy for patients with acute myocardial infarction.

Authors:  Ali Maleki; Arman Shariari; Masoumeh Sadeghi; Negin Rashidi; Farshid Alyari; Saeid Forughi; Behjat Nabatchi; Reza Ghanavati
Journal:  ARYA Atheroscler       Date:  2012
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.